

## Saskatchewan Immunization Manual Amendments **August 2021**

**Instructions:** Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

### **Chapter 5 –Immunization Schedules**

- P. 1 – Section 1.1 Routine Imms Schedule for Infants, Children and Adolescents
  - *Varicella removed table as were former related footnotes #5, 6 and 8.*
  - *Other footnotes renumbered accordingly.*
- P. 3 – Section 1.3A Pneu-C-13 schedule for Healthy Delayed Children
  - *Under 24-59 months, the second column has been revised in row 11 to **0 valid doses or incomplete vaccination schedule with any product** and row 12 **Completed age-appropriate vaccination with Pneu-C-u, Pneu-C-7, Pneu-C-10 or Pneu-C-13**. Third column row 12 now states **Considered up to date**.*
- P. 4 – Section 1.3B Pneu-C-13 schedule for Medically HR Delayed Children
  - *Footnote 3 removed as not relevant.*
- P. 6 – Section 1.5 Children 7-17 years who present for immunization
  - *Varicella removed from Grade 6 row.*
  - *Footnote 5A removed as no longer relevant. Footnote 5B now footnote 5.*
- P. 7 – Section 1.6 Adults who Present for Immunization
  - *Men-C-C removed from table and former footnote 6 removed.*
  - *Other footnotes renumbered accordingly.*
- P. 9 – Section 1.8 Publicly Funded Vaccine Eligibility Criteria
  - *Men-C-C bullets deleted, now only one bullet which states **Infants receive 1 dose at 1 year of age**.*
  - *Minimum age for Men-C-ACYW-135 vaccine changed to 6 weeks from 8 weeks of age.*
- P. 11 – Section 2.1 Minimum Intervals for Specific Vaccine Series
  - *Trade names removed from Men-C-ACYW-135 vaccine row.*
  - *Minimum age of 6 months added to IPV.*
- P. 30 – Appendix 5.4 PF Varicella Eligibility
  - *Reference to Grade 6 program removed from table.*

### **Chapter 6 – Precautions and Contraindications**

- P. 1 – Section 1.3 Client Assessment
  - *Second last bullet now states, **History of idiopathic thrombocytopenia within 6 weeks of a previous MMR/MMRV dose**.*

### **Chapter 7 immunization of Special Populations**

- P. 5 – Section 2.1 Bleeding Disorders
  - *Third bullet now states, **Always consult with the child's physician/specialist prior to MMR/MMRV immunization if they have had an episode of idiopathic thrombocytopenia that occurred within 6 weeks of a previous MMR/MMRV vaccine**.*
- P. 17 – Section 3.4 Islet Cell transplant
  - *Refer to SIM chapter 10 for specific vaccine eligibility added to bullet 2*
- P. 17 – Section 3.5 Solid Organ/Tissue Transplants
  - *Refer to SIM chapter 10 for specific vaccine eligibility added to bullet 2.*
- P. 35 – Appendix 7.1 Page 35
  - *HA program – Targeted Community definition revised to match SIM chapter 10 definition.*
- P. 39 Appendix 7.4 High Dose HB renal algorithm
  - *Added to ENGERIX-B box – New Footnote – **check for same lot #s and expiry dates**.*
- P. 41 – Appendix 7.6 Adult Stem Cell Transplant Immunization Recommendations
  - *Varicella vaccine is no longer contraindicated*
  - *Herpes zoster (SHINGRIX®) vaccine added to table, it is not publicly funded.*

## Saskatchewan Immunization Manual Amendments **August 2021**

### **Chapter 8 Administration of Biological Products**

- P. 15 – Section 2.4.3 Ventrogluteal
  - Introduction revised:
    - Do not use this site for vaccine administration. Active immunizing agents should not be administered into the gluteal muscle.
    - The ventrogluteal site is the preferred site for the IM injection of large volumes of immune globulin preparations (i.e., Ig, HBIg, RabiG, Tlg, Varig). Appropriate site selection of the gluteal muscle is necessary to avoid injury to the sciatic nerve.
    - This site can be used in those over 7 months of age.
    - This muscle is accessible in the supine, prone, and side lying position.
- P. 16 – Section 2.4.4 Dorsogluteal
  - Introduction revised:
    - Do not use this site for vaccine administration. Active immunizing agents should not be administered into the gluteal muscle.
    - The dorsogluteal site is only to be used for the IM injection of large volumes of immune globulin preparations when the ventrogluteal and vastus lateralis sites have had maximum volumes of an immune globulin preparation injected and an additional volume still needs to be administered. This is due to the possibility of sciatic nerve injuries when the injection is done in the dorsogluteal site.
    - This site should only be used in individuals over 5 years of age.

### **Chapter 10 Biological Products**

- TOR first page
  - [Third and Fourth COVID-19 Dose Recommendations for Travellers](#) added.
  - Proper abbreviations added to Shingrix (RZV) and Zostavax (LZV) vaccines
- TOR second page
  - HPV-4 removed
  - Influenza vaccines updated for 2021-22 season.
- AstraZeneca COVISHIELD COVID-19 vaccine
  - [Refer to Third and Fourth COVID-19 Dose Recommendations for Travellers in this chapter](#) added to Schedule section.
  - GBS added to possible reactions row.
  - NACI statement date and link updated.
- Moderna COVID-19 vaccine
  - [Refer to Third and Fourth COVID-19 Dose Recommendations for Travellers in this chapter](#) added to Schedule section.
  - NACI statement date and link updated.
- Pfizer COVID-19 vaccine
  - Children born in 2009 are eligible for immunization before 12 years of age.
  - [Refer to Third and Fourth COVID-19 Dose Recommendations for Travellers in this chapter](#) added to Schedule section.
  - NACI statement date and link updated.
- **NEW Page!** [Refer to Third and Fourth COVID-19 Dose Recommendations for Travellers](#) for guidance to complete series for Saskatchewan resident and Lloydminster residents who received Saskatchewan Immunization Services.
- Act-Hib and HIBERIX
  - Footnote #2 now reads: [The 18 month reinforcement dose may be given at 12 months if there is an 8 week interval following the previous dose.](#)
- SHINGRIX
  - Abbreviation changed to RZV.

## Saskatchewan Immunization Manual Amendments **August 2021**

- Zostavax II
  - Abbreviation changed to LZV.
- Gardasil (HPV-4) removed.
- Non-Publicly Funded Influenza Vaccines for 2021-22 season – updated for licensed vaccines.
- FluLaval Tetra, FluZone Quadrivalent and FluZone High Dose Quadrivalent – updated for 2021-22 season.
  - Note that Flu HD is quadrivalent and a 0.7 ml dose.
- MMR II, PRIORIX, PRIORIX Tetra and ProQuad
  - Thrombocytopenia statement under precautions now reads: Physician-diagnosed thrombocytopenia within 6 weeks after first dose of a MMR-containing vaccine.
- Menjugate Liquid and NeisVac –C
  - Indication for those born 1993-01-01 to 2000-09-30 removed as ineligible after age 21 years.
- PREVNAR p. 1 of 2
  - Wording for section of healthy and medically high-risk children 24-59 months first rows of second column now align with revised chapter 5 Pneu-C-13 scheduling pages and state: 0 valid dose or incomplete vaccination schedule with any product.
- Varilrix and Varivax (first pages)
  - Reference to Grade 6 program removed.
- Updated product monographs:
 

AstraZeneca/COVISHIELD	INFANRIX hexa®	HAVRIX	ENGERIX-B	SHNIGRIX	MMR II
FluLaval Tetra	FluZone Quadrivalent	FluZone High Dose Quadrivalent	NIMENRIX	BEXSERO	
Trumenba	SYNFLORIX	IMOVAX Rabies	Rotarix	Adacel	Boostrix
				Boostrix-Polio	Typhim-V

### Chapter 14 – Appendices

- P. 21 – Appendix 14.3 Immunization Fact Sheets
  - Several updates: HA, HB, MMR, Men-C-C, Men-C-ACYW-135, Men B, Pneu-C-13, Rot-1, Tdap and Var because of updated product monographs or program changes (Var for Grade 6 student).